Literature DB >> 11339551

Cis and trans elements regulating expression of the varicella zoster virus gI gene.

H He1, D Boucaud, J Hay, W T Ruyechan.   

Abstract

We have identified cis- and trans-acting elements involved in the VZV IE62 protein-activated expression of the varicella zoster virus (VZV) gene which encodes the viral gI glycoprotein. The cis-acting elements include a non-canonical TATA box and a novel 19 base pair sequence located just upstream of the TATA element designated the "activating upstream sequence" or AUS. The AUS is a movable element and its presence results in IE62 activation of a chimeric promoter consisting of the VZV gC TATA box and the gI AUS. We have also determined that the VZV ORF 29 protein modulates the regulatory activity of the IE62 protein at the gI promoter. In combination with the IE62 transactivator, it yields a 10 to 15-fold increase in expression over the levels seen with the IE62 protein alone in T lymphocytes. The upmodulatory activity requires the presence of a 40 base pair sequence, designated the 29RE, which maps between positions -220 and -180 in the gI promoter. In this paper we review these and earlier findings from our laboratories concerning the regulation of the gI promoter.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11339551     DOI: 10.1007/978-3-7091-6259-0_7

Source DB:  PubMed          Journal:  Arch Virol Suppl        ISSN: 0939-1983


  11 in total

1.  A sequence within the varicella-zoster virus (VZV) OriS is a negative regulator of DNA replication and is bound by a protein complex containing the VZV ORF29 protein.

Authors:  Mohamed I Khalil; Ann Arvin; Jeremy Jones; William T Ruyechan
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

2.  T-cell tropism and the role of ORF66 protein in pathogenesis of varicella-zoster virus infection.

Authors:  Anne Schaap; Jean-Francois Fortin; Marvin Sommer; Leigh Zerboni; Shaye Stamatis; Chia-Chi Ku; Garry P Nolan; Ann M Arvin
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

3.  Absence or overexpression of the Varicella-Zoster Virus (VZV) ORF29 latency-associated protein impairs late gene expression and reduces VZV latency in a rodent model.

Authors:  Jeffrey I Cohen; Tammy Krogmann; Lesley Pesnicak; Mir A Ali
Journal:  J Virol       Date:  2006-12-06       Impact factor: 5.103

4.  Role of the IE62 consensus binding site in transactivation by the varicella-zoster virus IE62 protein.

Authors:  Kris White; Hua Peng; John Hay; William T Ruyechan
Journal:  J Virol       Date:  2010-02-03       Impact factor: 5.103

5.  Regulation of the varicella-zoster virus ORF3 promoter by cellular and viral factors.

Authors:  Mohamed I Khalil; Marvin Sommer; Ann Arvin; John Hay; William T Ruyechan
Journal:  Virology       Date:  2013-03-21       Impact factor: 3.616

6.  Regulation of the ORF61 promoter and ORF61 functions in varicella-zoster virus replication and pathogenesis.

Authors:  Li Wang; Marvin Sommer; Jaya Rajamani; Ann M Arvin
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

7.  Characterization of varicella-zoster virus gene 21 and 29 proteins in infected cells.

Authors:  Randall J Cohrs; Jeanne Wischer; Carrie Essman; Donald H Gilden
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

8.  Aberrant infection and persistence of varicella-zoster virus in human dorsal root ganglia in vivo in the absence of glycoprotein I.

Authors:  Leigh Zerboni; Mike Reichelt; Carol D Jones; James L Zehnder; Hideki Ito; Ann M Arvin
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-20       Impact factor: 11.205

9.  Cellular and viral factors regulate the varicella-zoster virus gE promoter during viral replication.

Authors:  Barbara Berarducci; Marvin Sommer; Leigh Zerboni; Jaya Rajamani; Ann M Arvin
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

10.  Promoter sequences of varicella-zoster virus glycoprotein I targeted by cellular transactivating factors Sp1 and USF determine virulence in skin and T cells in SCIDhu mice in vivo.

Authors:  Hideki Ito; Marvin H Sommer; Leigh Zerboni; Hongying He; Dwayne Boucaud; John Hay; William Ruyechan; Ann M Arvin
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.